Ahmed Sayed

PGY-1 @ Rochester Gen Hospital via @MethodistHosp @Almallah_Labs via @AinshamsMed 🇪🇬 | #cardiology🫀 #R💻 #football⚽️|Tweets My Own.

[Javed Butler @JavedButler1]

https://t.co/lFISAcAwTO Confirming and quantifying what was suspected - heart failure is evolving. Significant evidence generation implications.

[NEJM @NEJM]

Original Article: Beta-blockers after Myocardial Infarction with Normal Ejection Fraction https://t.co/1LiJFFvnm3

@AHAScience | #AHA25

[Ahmed Sayed @ASayedMD]

🙏🙏Immensely grateful for the generous support and guidance from Dr. Ann Marie Navar, @virani_md, @ericpetersonMD, and @dramitkhera 🙏🙏

And many thanks to @JAMAInternalMed for offering an avenue to share our findings

[Ahmed Sayed @ASayedMD]

How does the move to PREVENT for ASCVD risk estimation affect aspirin use❓

📜https://t.co/Gz9TGiW6sp

1⃣ >80% eligible for 1ry prevention aspirin based on a PCE risk >10% would no longer be eligible w/ PREVENT

2⃣ Most current aspirin users don't qualify under either calculator

[John Mandrola, MD @drjohnm]

Biggest move today in clinic:

Stopping ASA in pts on DOAC

AQUATIC = most important trial of the year.

https://t.co/XcoO3j8Mb0

[Anil Makam @AnilMakam]

Here are my takeaways for the 7 most relevant and important #ESCCongress2025 for generalists

AQUATIC, HI-PRO, RETREAT-FRAIL, DIGIT-HF, DAN-RSV were most practicing changing

POTCAST was most contentious - not as billed

[Ahmed Sayed @ASayedMD]

🙏Incredibly grateful to @almallahmo for supervision , @MalekNayfeh, Fares AlAhdab, Mahmoud Al Rifai, @DmitryAbramovMD, @FudimMarat , @YasMoayedi, @RayanYousefzai for their incredible support, and to @JACCJournals CV imaging for the opportunity to publish our work🙏

[Ahmed Sayed @ASayedMD]

Do heart transplant patients always need invasive angio to screen for graft vasculopathy❓

📜https://t.co/JVR5PRa1VN

In this meta-analysis, CTA/PET had pretty respectable sensitivity/NPV for ruling out graft vasculopathy compared to a gold standard of invasive angiography.

[Gary Collins @GSCollins]

NEW PAPER in @bmj_latest "Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide"

--> https://t.co/4YGRasQVrx

#methodologymatters

[CircImaging @CircImaging]

Over the past 41 years, death due to ischemic heart disease did not decline in countries with low socioeconomic development, research shows @ASayedMD @MethodistHosp @virani_md @ErinMichos @annmarienavar @DrLaPrincess https://t.co/mDlDtJTqov

[Ahmed Sayed @ASayedMD]

🙏🙏Incredibly thankful to @almallahmo and Dr. Al Rifai for their supervision & guidance on this; and to my brilliant colleague @MariaAlwan_ 🙏🙏

And thank you to @EHJCVIEiC for allowing us to share our findings!

[Ahmed Sayed @ASayedMD]

1/4🧵

In patients undergoing cardiac stress testing w/ PET, does rest flow matter❓

In an analysis of >8k patients, we find that it does, esp. in patients with a preserved EF.

Link📜: https://t.co/05Nxx0K95o
@almallahmo @MariaAlwan_ @MyASNC @MethodistHosp @EHJCVIEiC

[Ahmed Sayed @ASayedMD]

Patients with a normal-ish EF could be further stratified as being at a *truly* low-risk of events or at intermediate risk depending on their rest flow.

In contrast, patients with a depressed EF had a uniformly high rate of events regardless.

[Fiyyaz Ahmed-Jushuf @fiyyazAJ]

𝐃𝐒𝐄 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐬 𝐢𝐧 𝐎𝐑𝐁𝐈𝐓𝐀-𝟐: Stress echo ischemia identifies who 𝘳𝘦𝘢𝘭𝘭𝘺 benefits from PCI. 📖 𝐉𝐮𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐢𝐧 #𝐉𝐀𝐂𝐂: https://t.co/SoNkeJ0zVW
@rallamee @mshunshin @rajkumar_chris @MikeFoley89 @FloSimader @ShaynaChotai

[Malak Munir @MalakMunirMD]

An incredible experience at #DDW2025! Privileged to share our work on #pancreaticcancer, Fatty Pancreas, and #colorectalcancer

With 3 oral presentations, and 3 poster presentations ✅

Immensely grateful for the mentorship and support of Dr. @SriGaddamMD 🙏🏼

[Gil Carvalho MD PhD🌈🇵🇸 @NutritionMadeS3]

New genetic analysis in 200k people over 14 years

▶️apoB + lp(a) best capture lipid-mediated CV risk

▶️LDL particle size adds no additional info when apoB is accounted for
https://t.co/Kv7sUxAcmv

[Circulation @CircAHA]

Intensive LDL-C lowering with Evolocumab may lead to greater relative reduction in cardiovascular events in patients with autoimmune or inflammatory diseases. @AndreZimerman @bweber04 @analaurakunzler
@rgiuglaino https://t.co/oYtX8Vbxqu

[Ahmad Kassar @Ahmadkassar7]

Just in time for #HRS2025‼️

Excited to share our latest paper published in @AmericanHeartJ and honored to be first co-author with Dr. Bockus.
Looking forward to presenting our work in San Diego.

https://t.co/n3AsBU4bNw

@NazemAkoum @UWMedHeart